Brisou G, Paillassa J, Bernard S, Tournilhac O, Fornecker L-M, Maloisel F, Gastaud L, Durot E, Tempescul A, Braun T, Ivanov V, Cherel B, Serrier C, Delage J, El Yamani A, Delapierre B, Lebras L, Lestang E, Villesuzanne C, Agape P, Escure G, Fouillet L, Nicol C, Olivier G, Levy A, Le Bris A-S, Cassuto O, Jacquemelle L, Haioun C, Herbaux C. Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study. haematol [Internet]. 2025Oct.1 [cited 2025Dec.5];110(10):2400-12. Available from: https://haematologica.org/article/view/12058